Member Info for fatprofits

Your first ever post on LSE, eh.

A very astute comment.

If they planned to rebase in 2022 post split, they should have

provided guidance, or at least a strong indication of the planned first
year payouts for the two divisions.

They could have couched that in the context of business performance over
the next 12 months etc.

Successful investors remain flexible and capable of changing their
minds in a blink of an eye, if the facts change.

And the fact is GSK are guiding lower for FY 2021, again.

If you had been quick you could have sold and
had the option of now buying back.

I have Not suggested anyone Sell ot clicked a single Sell rec on GSK.

FY 2020 EPS - Fell by 4% CER.

Now GSK are guiding lower for FY 2021.

What part of my posts do you disagree with or that

are factually incorrect?......waiting.

Fats calls it as it is.

And guidance for a futher decline in FY2021.

Shambolic imv

.

Over the last 10 years.

Pay no attention to those who blame the London market.

Firstly there are global capital flows, as any 15 year old GCSE student known

and secondly, why would the market re-rate No overall growth.

Falling EPS, dividend cut.

Falling earnings, look at the EPS number.

Why should it be re-rated, there is no overall growth.

Very lucky, had to cancel the open limit orders and
reloaded to sell the lot at market price.

.

Very luckily other pharma companies delivered before GSK on COVID-19.

How many more tens of thousands of lives would be lost before 2022
without existing Covid-19 vaccine options.

We are indebted to AZN, Pfizer and Moderna.

AZN has outperformed the wider UKX over 1, 5 and 10 years.

Currently there is no longer term downtrend. Like everything else that can change.

I've made a complaint to LSE about that last post.

Hopefully they take action.

The mirror slips.

Hopefully posters can see the true TR64.

100,000 plus UK COVID deaths, tens of thousands of long Covid-19
cases, many of those look to have irreparable lung damage -
my other half works in the sharp end of healthcare

The AZN vaccine will save thousands of lives.

It's the backbone of the UK's fantastic vaccination effort -

well done Oxford AstraZeneca.

Remove the unwarranted parabolic vaccine spike

and I dont see any downtrend, let alone a long term one
(this can change obvs).

The longer term uptrend began circa summer 2013 @ approx £31 a share.

I maintain there may be an impact on revenues from COVID-19
potentially delaying treatment options and affecting treatment referrals.

IF so, is that factored in to the SP already?

Not confident in answering that one.

Fewer cancer referrals in the UK, significantly fewer in some
areas.

I would guessestimate this mirrors the experience in multiple
other non Asian countries.

This is likely to be impacting on some revenues.

To what extent?, more should be clearer on the next update.

Appears to have just reached the conclusion that AZN

will Not make a commercial return from the Covid-19 vaccine.

AZN made that crystal clear in 2020 and underlined it in Red.

I've highlighted this for months. The parabolic spike was
completely unwarranted.

Some are a country mile behind in reaching their conclusions.

Beware the posting of those that seek to appear clever.

Very easy to check posting history to see how many good calls,
or otherwise, a particular poster has made.

* a lot can happen between now and then so
they may be subject to significant change.